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Male Infertility
VCY Lee, MRCOG, FHKAM(OG); EHY Ng, MD, FRCOG; PC Ho, MD, FRCOG
EPIDEMIOLOGY
Infertility generally affects one in seven 
couples and is a growing problem world-
wide.1,2 This is illustrated by the increase 
in the number of assisted reproductive 
technology (ART) treatment cycles world-
wide in 2009–2010, ranging from an in-
crease of 5.9% to over 100%.3–5 Male sub-
fertility is one of the major causes, as a 
sole factor accounting for 29.7% and as a 
contributor for another 10.3–29.7% in the 
United Kingdom and Hong Kong.3,5 There 
is some evidence suggesting that there 
might be a decline in semen concentration 
of men born in the 1930’s to 1980’s.6–8
DEFINITION
In the investigation of an infertile cou-
ple, semen analysis has all along been 
performed for the assessment of the 
fertility status of the male partner. The 
World Health Organization manual for 
examination and processing of human 
semen has been recognized as the global 
standard for semen analysis. The most 
recent World Health Organization man-
ual for semen analysis was published 
in 2010 and set the lower ‘reference’ 
limits of semen parameters according to 
the fifth centile of men, whose partners 
had a time-to-pregnancy of 12 months or 
less, worldwide (Tables 1 and 2).9 There-
fore, men with semen parameters below 
the lower reference limits (other than 
those with azoospermia) are not neces-
sarily infertile. It is recommended that 
semen samples should be collected by 
masturbation after 2–7 days of sexual 
abstinence without the use of lubri-
cants. The process of analysis should be 
carried out within 1 hour of collection, 
and two or more samples are required 
especially for abnormal results. 
AETIOLOGY
The aetiology of male infertility can be 
classified as pre-testicular, testicular, and 
post-testicular (Table 3).10,11 The manage-
ment of male infertility should be based on 
the aetiology if it is known. However, the 
exact aetiology is often not known. 
Pre-testicular causes include hy-
pogonadotrophic hypogonadism due to 
Kallmann syndrome (with anosmia), brain 
tumours, radiotherapy for brain tumours, 
gene mutations (such as luteinizing hor-
mone receptor mutation), and idiopathic 
hypogonadotrophic hypogonadism. Post-
testicular causes are mostly obstructive, 
which include iatrogenic obstruction (va-
sectomy), congenital bilateral absence of 
the vas deferens (CBAVD), and post-in-
flammation or infection. Testicular causes 
include genetic causes, infection, system-
ic diseases, and trauma. Coital dysfunc-
tion in the form of erectile and ejaculatory 
dysfunction is another possible cause of 
infertility. Retrograde ejaculation can be 
due to anatomical causes including blad-
der neck surgery and posterior urethral 
valves, neurogenic causes including dia-
betes mellitus and spinal cord injury, and 
drug-induced like alpha-receptor blockers 
and antipsychotics.12
CLINICAL WORKUPS
History and Physical Examinations
When infertile couples first attend the 
The exact aetiology of male infertility is 
often not known.
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infertility clinic, semen analysis reports 
should preferably be available for review. 
A detailed clinical history and clinical ex-
amination of the men should be conduct-
ed, and further investigations would be 
dependent on the severity of abnormal pa-
rameters. Clinical history includes history 
of torsion, trauma and infection/inflamma-
tion of the testicles (which may damage 
the testis), drug history like chemothera-
py/radiotherapy, surgical history such as 
orchidopexy for cryptorchidism, and social 
history especially smoking history, sauna 
habit and occupation. Physical examina-
tion should include the size and consist-
ency of the testes (which are indicators for 
testicular function), any distension of the 
epididymis (which may indicate obstruc-
tive causes), and the absence of vas defer-
ens (which is indicative of CBAVD). 
Genetic Tests
Genetic tests, including karyotype and Y 
chromosome microdeletion test, should be 
arranged if there is severe oligozoosperm-
ia or azoospermia. Karyotype abnormal-
ity and Y microdeletion account for about 
15–21% and 8.5–10% of non-obstructive 
azoospermia (NOA), respectively.10,13 
Klinefelter syndrome (KS), including 80% 
non-mosaic type and 20% mosaic type, is 
the major cause of karyotype abnormal-
ity.14 Most Y chromosome microdeletions 
occur on the long arm (q) and are subdi-
vided into three azoospermia factor (AZF) 
regions: AZFa, AZFb, and AZFc.15 There is 
evidence that the prevalence of karyotype 
anomalies and AZF deletions increases 
with decrease in semen concentrations. 
The prevalence of karyotype anomalies in 
oligozoospermic men with semen concen-
tration below 5 million/mL is 8%, which 
increases to 15% in azoospermic men, 
while the prevalence of AZF deletion also 
increases from 5% to 10%.10 Based on the 
prevalence of abnormalities of karyotype 
and Y microdeletion in 295 oligozoosper-
mic or azoospermic men from Hong Kong 
with different sperm concentrations,13 we 
recommend performing a karyotype and Y 
microdeletion test only if the semen con-
centration is below 2 million/mL. 
Screening for cystic fibrosis genetic 
mutation should be done in men with 
CBAVD. The prevalence of cystic fibrosis 
transmembrane conductance regulator 
(CFTR) gene in Caucasian men with CBAVD 
is high, ranging from 71% to 87% in differ-
ent Western countries,16,17 and it warrants 
proper testing followed by screening of 
the female partner if a mutation is present. 
However, the prevalence of cystic fibrosis 
and the carrier rate of CFTR gene mutation 
in the Chinese population are very low. As 
Table 1. Semen parameters according to the World Health Organization (2010)
Parameter Lower reference limits 
(95% confidence interval)
Semen volume, mL 1.5 (1.4–1.7)
Total sperm number, × 106 per ejaculate 39 (33–46)
Sperm concentration, × 106/mL) 15 (12–16)
PR, % 32 (31–34)
Total motility (PR + NP), % 40 (38–42)
Sperm morphology (normal forms), % 4 (3.0–4.0)
Vitality (live spermatozoa), % 58 (55–63)
NP = non-progressive motility; PR = progressive motility.
Table 2. Nomenclatures of abnormal semen parameters according to the 
World Health Organization (2010)
Oligozoospermia Sperm concentration < 15 × 106/mL or total sperm count 
< 39 × 106/mL
Asthenozoospermia < 32% progressive motility or < 40% total motility
Teratozoospermia Normal sperm morphology < 4%
Azoospermia No spermatozoa found in ejaculate
Cryptozoospermia Spermatozoa absent from fresh preparations but ob-
served in a centrifuged pellet
Aspermia Absence of ejaculate (either no ejaculate or retrograde 
ejaculation)
Any combinations of oligozoospermia, asthenozoospermia and teratooospermia mean the combination of abnormal parameters 
shown in semen analysis.
Continuing Medical Education
JPOG SEP/OCT 2???????????
the main aim of genetic testing is to avoid 
full-blown cystic fibrosis in the offspring 
by prenatal diagnosis or preimplantation 
genetic diagnosis if the partner is also a 
carrier of the mutation, the tests for the 
mutation would not be necessary in the 
Chinese. 
Hormonal Tests
Hormonal tests, including those for folli-
cle-stimulating hormone (FSH) and testos-
terone, should be considered in azoosper-
mic men. High gonadotrophin and normal/
low testosterone levels (hypergonado-
trophic hypogonadism) indicate gonadal 
failure, and low gonadotrophin and low 
testosterone levels indicate hypogonado-
trophic hypogonadism. Hormonal tests 
are likely to be normal in azoospermia 
of obstructive aetiology. The treatment 
would be completely different. However, 
there is controversy over the use of hor-
monal levels and other factors like inhibin 
B and anti-mullerian hormone to predict 
the success in surgical retrieval of sperm 
in men with gonadal failure, and there is 
no consensus on the cut-off value of these 
tests in the prediction.18–21 The associa-
tion of hyperprolactinaemia with or with-
out pituitary adenoma and male infertility 
is not clearly defined, yet hypogonadism 
caused by hyperprolactinaemia (resulting 
in erectile dysfunction) may be a contrib-
uting factor.22 Dopamine agonists, such as 
bromocriptine, can normalize the prolactin 
level. However, they would not improve 
the infertility problem in terms of hormo-
nal profiles, semen parameters and preg-
nancy outcome in hyperprolactinaemic pa-
tients or idiopathic infertile men.22,23
Miscellaneous
Transrectal ultrasound scanning is used to 
confirm the diagnosis of obstructive caus-
es and also to delineate the extent of ob-
struction to see if reconstructive surgery 
is feasible.24
Tests on sperm DNA integrity and 
fragmentation are some of the most con-
troversial investigations in male infertil-
ity. It has been shown that fertilization 
and subsequent embryo development de-
pend in part on the inherent integrity of 
the sperm DNA, and there seems to be a 
threshold of sperm DNA damage in terms 
of DNA fragmentation, abnormal chroma-
tin packaging and protamine deficiency 
Table 3. Aetiology of male infertility
Pre-testicular causes
?? Idiopathic (~50%) (idiopathic hypogonadotrophic hypogonadism)
?? Hypothalamic-pituitary-gonadal axis problems (Kallmann syndrome; gene  
 mutations, eg, luteinizing hormone receptor mutation; brain abnormality, eg,  
 pituitary tumour)
Testicular causes
?? Congenital including anorchia and cryptorchidism
?? Genetic diseases (chromosomal including Klinefelter syndrome and balanced  
 translocation; Y microdeletion)
?? Infection/inflammation (eg, tuberculosis, prostatitis)
?? Systemic diseases or medical therapy including chemotherapy and  
 radiotherapy
?? Trauma to testicles or torsion
?? Varicocele
Post-testicular causes
?? Congenital bilateral absence of the vas deferens (with or without cystic  
 fibrosis mutation)
?? Iatrogenic (post-vasectomy)
?? Post-inflammation (epididymitis)
Coital dysfunction
?? Erectile or ejaculatory problem
?? Retrograde ejaculation (anatomical causes, eg, surgery to prostate and 
 bladder neck, and posterior urethral valves; neurogenic causes, eg, diabetes  
 mellitus and spinal cord injury; drug-induced, eg, alpha receptor blockers for  
 benign prostate hyperplasia and antipsychotics)
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resulting in impaired embryo develop-
ment.25,26 The American Society for Repro-
ductive Medicine recommends that there 
is no proven role for routine DNA integrity 
testing as the results do not predict preg-
nancy outcomes in spontaneous concep-
tion and ART treatment cycles and there 
is no effective treatment available for 
abnormal DNA integrity.27 Therefore, tests 
for DNA fragmentation should not be used 
routinely for infertility investigations.
TREATMENT
Treatment would depend on the aetiology 
of the male factor, the severity of abnor-
malities in semen parameters, and the 
presence of female factors such tubal sta-
tus and woman’s age. In men with mildly 
abnormal semen parameters to severe 
oligoasthenoteratozoospermia, intrauter-
ine insemination (IUI) and in vitro fertiliza-
tion (IVF) with or without intracytoplasmic 
sperm injection (ICSI) can improve the 
pregnancy rate. In men with azoospermia, 
treatment would be dependent on the un-
derlying reasons. The algorithm is shown 
in Figure 1.
Azoospermia
Azoospermia can be classified as NOA 
and obstructive azoospermia (OA). NOA 
can further be classified as due to go-
nadal failure or hypogonadotrophic hypo-
gonadism. Surgical retrieval of sperm is 
the treatment for OA and gonadal failure. 
There are different techniques including 
percutaneous epididymal sperm aspiration 
(PESA), microsurgical epididymal sperm 
aspiration (MESA), testicular sperm aspi-
ration (TESA)/testicular sperm extraction 
(TESE), and microscopic or microdissection 
testicular sperm extraction (mTESE).
Obstructive azoospermia. PESA 
and MESA are used in OA to retrieve 
epididymal sperm from distended tubules 
in the epididymis. PESA can be done un-
der local anaesthesia. It involves percu-
taneous puncture of the scrotal skin into 
the epididymis using a fine needle (eg, 
26-gauge), and aspiration can be repeated 
in multiple sites.28 MESA involves an open 
operation under an operating microscopy 
and is able to retrieve greater number of 
sperm and minimize contamination of the 
sample with blood. Some urologists ad-
vocate MESA over PESA in patients with 
OA who would consider more than one IVF 
cycle, as MESA typically results in sperm 
with adequate motility for effective cryo-
preservation for multiple treatment cy-
cles.29 There is so far no direct comparison 
between MESA and PESA. A Cochrane re-
view commented that there is only scarce 
evidence on the choice of surgical tech-
nique in sperm retrieval.30 So, the choice 
of surgical technique would mainly depend 
on personal preference and surgical ex-
pertise. If no sperm is obtained from the 
epididymis, direct retrieval of sperm from 
the testicles can be performed in the same 
setting.28 MESA can be combined with re-
constructive surgery in selected cases.31 
NOA – gonadal failure. Surgical re-
trieval of testicular sperm is the mainstay 
of treatment for hypergonadotrophic hypo-
gonadism. TESE/TESA involves retrieval 
of sperm directly from the testicles using 
different techniques. mTESE requires an 
operation under microscopy and helps in 
visualization of the larger, more opaque, 
whitish tubules, presumably containing 
more intratubular germ cells with active 
spermatogenesis. A higher retrieval rate 
was reported with mTESE than with con-
ventional TESE.32,33 The successful retriev-
al rate in NOA patients is typically quoted 
as less than 50%, although a higher re-
trieval rate may be possible with mTESE. 
The use of TESE or mTESE, together 
with ICSI in IVF treatment cycles, is the 
only option for KS men to bear their own 
genetically linked children, and the suc-
cess rate of surgical retrieval of sperm 
was reported to be similar with other NOA 
men with no karyotype abnormality.34,35 
One group reported a higher retrieval rate 
of 68% and 72% in KS men using mTESE 
or conventional TESE, respectively.36,37 Not 
only is karyotype abnormality a predictor 
of the success of retrieval, the presence 
of AZF microdeletions on the Y chromo-
some is also a good predictor. Men with 
AZFc microdeletions alone have a similar 
success rate of surgical sperm retrieval 
on TESE, while those with AZFa or AZFb 
microdeletions will almost definitely have 
no sperm retrieved for ICSI.15,38 Therefore, 
genetic tests would be extremely useful in 
counselling before the surgical retrieval of 
sperm and for examining the inheritance 
of the mutation in the next generation.
NOA – hypogonadotrophic hypo-
gonadism. Induction of spermatogenesis 
with pulsatile gonadotrophin-releasing 
hormone (GnRH) or gonadotrophins, ie, 
human chorionic gonadotrophin (hCG) or 
FSH, is the treatment of choice for men 
with hypogonadotrophic hypogonadism.39 
Both treatments have been shown to in-
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duce spermatogenesis successfully.39–41 
Although some investigators showed that 
the use of pulsatile GnRH was related to 
a greater testicular growth and faster in-
duction of spermatogenesis, the ‘take-off’ 
for this kind of treatment is limited by the 
high cost of the drug and the difficulty in 
handling the pump system. The high suc-
cess rate of gonadotrophins, ranging from 
53% to 78%, implies that it is the treat-
ment of choice in some localities.42,43 The 
usual recommended treatment consists of 
twice weekly injection of hCG 1,500 IU to 
2,000 IU, with further dosage increment 
after review of the hormonal levels in 4 
to 6 weeks’ time. In men suffering from 
hypogonadotrophic hypogonadism after 
puberty, hCG alone is usually sufficient 
Figure 1. Algorithm
Submit two semen 
samples
Normal
Abnormal semen 
parameters
AzoospermiaCoital problem 
– erectile dysfunction
– ejaculatory failure
Retrograde ejaculation
Counselling 
Drug treatment 
Penile vibration/elec- 
  troejaculation for IUI/        
  IVF (treat accordingly)
Normal FSH and  
 testosterone  
 levels
Low FSH levels 
Low testosterone  
 levels
Meet IUI 
criteria*
Obstructive 
causes
Hypogonadotrophic
hypogonadism
Testicular 
failure
Genetic tests
Tubes patent
IUI
No sperm
YES NO
TESE +
IVF + ICSI
Use of donor 
sperm
MESA + IVF
+ ICSI
Spermatogenesis 
induction
IVF ± ICSI 
Hormonal tests and     
 genetic screening if     
 indicated
Abnormal
High FSH levels 
Normal or low        
 testosterone  
 levels
Tubes blocked
FSH = follicle-stimulating hormone; ICSI = intracytoplasmic sperm injection; IUI = intrauterine insemination; IVF = in vitro fertilization; MESA = microsurgical epididymal sperm aspiration; TESE = testicular 
sperm extraction.
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for induction of spermatogenesis, with the 
median sperm count of 8 million/mL, when 
their partners get pregnant.43 Whereas in 
men suffering prepubertal hypogonadism, 
the treatment usually requires FSH to-
gether with hCG injection in order to in-
duce spermatogenesis.42,43 Prior androgen 
administration was shown to be related 
to a slower induction of spermatogenesis. 
The average treatment duration may be up 
to 25 to 30 months before the men can im-
pregnate their partners.43 
Abnormal Semen Parameters
The treatment would be dependent on the 
severity of abnormal semen parameters, after 
taking into consideration the woman’s age 
and tubal status. IUI and IVF can be offered.
Artificial insemination using hus-
band’s semen may be performed with 
intravaginal insemination, intracervical in-
semination, or IUI. IUI is currently the most 
commonly performed method in the man-
agement of male infertility. It is used in 
men with 2–5 million total motile sperma-
tozoa after processing. The criteria differ 
in various clinics, with the lowest thresh-
old of 1 million total motile spermatozoa in 
the inseminate.44 Sperm morphology (strict 
criteria) seems to be predictive of the suc-
cess rate of IUI, with a significantly higher 
pregnancy rate when the morphology is ? 
4%.45 However, different centres should 
have their own criteria for recruitment 
for IUI. There is contradicting evidence on 
the protocol of IUI. It was suggested that 
IUI has no significant benefit over timed 
intercourse and ovarian stimulation does 
not improve the outcome.46 However, it 
was shown that gonadotrophin for ovar-
ian stimulation offers a significantly bet-
ter pregnancy outcome than does anti-
oestrogen, while there was no difference 
between anti-oestrogen and aromatase in-
hibitor. There was also no benefit in using 
either GnRH agonist or antagonist in IUI in 
terms of pregnancy rate. Low-dose gonad-
otrophin was suggested, as doubling the 
dose would only increase the complication 
rate, namely multiple pregnancy rate and 
ovarian hyperstimulation syndrome, but 
not the pregnancy rate.47 As there is no 
robust evidence, further properly designed 
trials are needed to confirm the present 
suggestions.
In vitro fertilization consists of fol-
licular development with various ovarian 
stimulation protocols, oocyte retrieval, fer-
tilization inside laboratory environment, and 
transfer of embryos to the uterine cavity. 
Since the first report of the use of ICSI in 
human that resulted in a pregnancy, ICSI has 
become the routine practice for severe male 
infertility.48 ICSI is the procedure of inject-
ing a single sperm directly into an oocyte. 
Although sperm morphology was reported 
to be more relevant to fertilization failure,49 
the prediction of fertilization failure by mor-
phology or other parameters is still poor50 
and so different centres have their own set 
of criteria for using ICSI. The development 
after fertilization including the blastulation 
rate was shown to be not affected by sperm 
morphology.51 A study showed that the use 
of ICSI in non-male infertility was associ-
ated with a lower implantation rate when 
compared with conventional insemination52; 
thus, ICSI should be reserved for severe 
male factor infertility. As shown by a recent 
review, there is a slight increase in de novo 
chromosomal abnormalities and the major 
congenital malformation rate is similar for 
IVF and ICSI (~3–4%).53
Miscellaneous therapies. (a) An-
tioxidant. There is evidence suggesting 
that reactive oxygen species (ROS)-me-
diated damage to sperm is a significant 
contributing pathology in 30–80% of male 
factor infertility. There are two principal 
mechanisms of ROS-related infertility. 
Firstly, ROS damage the sperm membrane, 
impairing the sperm’s motility and ability 
to fuse with the oocyte. Secondly, ROS 
causes sperm DNA damage, compromising 
the paternal genomic contribution to the 
embryo.54 Raised ROS levels are usually 
associated with smoking, genital tract or 
systemic infections, and varicocele.55,56 It 
has been shown that embryos formed from 
fertilization with sperm having high DNA 
damage are of poorer quality and have a 
decreased cleavage rate.57 
As antioxidants (namely vitamins C 
and E, folate, zinc, selenium, carnitine, 
and carotenoids) are scavengers of ROS, 
they have been studied in male factor in-
fertility. A Cochrane review indicated that 
the use of antioxidants, such as vitamin 
C and zinc, may improve the pregnancy 
outcome in ART cycles based on evidence 
from small randomized trials, and larger 
trials are needed to confirm the results.58 
There is also evidence of improvement 
of sperm parameters and spontaneous 
conceptions. However, the trials were all 
small and had significant methodological 
and clinical heterogeneity. Drawing a con-
clusion from these trials may not be ap-
propriate,59 and so antioxidants should not 
be recommended routinely.
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(b) Treatment of varicocele. There 
is a hot controversy on the effectiveness 
of varicocele treatment (including surgical 
and radiological methods) on semen pa-
rameters and pregnancy outcomes. Some 
investigators reported no improvement60,61 
while others showed significant improve-
ment in spontaneous conceptions.62–64 
According to the recommendation of the 
American Society for Reproductive Medi-
cine, treatment of varicocele should 
be considered if all of the following 
conditions are met: (1) the varicocele 
is palpable on physical examination of 
the scrotum; (2) the couple has known 
infertility; (3) the female partner has 
normal fertility or a potentially treat-
able cause of infertility; and (4) the male 
partner has abnormal semen parameters 
or abnormal results from sperm function 
tests. Moreover, it explicitly expressed 
that varicocele treatment for infertility 
is not indicated in patients with normal 
semen qualities and a subclinical vari-
cocele.65 As some trials included men 
with subclinical varicocele, the outcome 
in men with clinical varicocele would be 
difficult to interpret. Nevertheless, the 
evidences come from the comparison 
between expectant management and 
varicocele treatment in spontaneous 
conception while there is no evidence of 
the effectiveness in ART cycles includ-
ing IUI and IVF cycles. Different surgical 
approaches were compared in one ran-
domized trial, which revealed that sub-
inguinal microsurgical varicocelectomy 
had better outcomes than open inguinal 
and laparoscopic varicocelectomy.66
(c) Lifestyle modification. To-
bacco smoking is associated with male 
factor infertility, probably related to 
the increase in ROS and DNA damage. 
There are many studies showing poorer 
semen quality in smokers compared with 
non-smoking counterparts.67,68 However, 
there is no evidence showing that quit-
ting smoking may improve semen param-
eters.67 Nonetheless, smoking has been 
shown to reduce significantly the preg-
nancy rate in IVF treatment cycles.69 It 
would be sensible to advise both partners 
to quit smoking before commencement 
of treatment cycles, not only for the ART 
cycles but also for their general health.
Coital Dysfunction
Psychosexual counselling is the main-
stay of treatment for coital dysfunction. 
The use of phosphodiesterase inhibi-
tors, such as sildenafil and vardenafil, 
should be considered in men with erec-
tile dysfunction after excluding contrain-
dications.70 If these first-line treatment 
methods fail, intra-penile injections, 
vacuum constriction devices and im-
plantation of a penile prosthesis for the 
treatment of their erectile dysfunction 
can be considered.71 If the couple fails to 
conceive naturally after these measures 
or if the semen quality is not good, ART 
like IUI or IVF may also help. 
For retrograde ejaculation, treat-
ment of the underlying causes is need-
ed. Drug treatment is the first-line treat-
ment, including alpha agonistic drugs 
and parasympathomimetics. If the drug 
therapy fails, penile electrovibration 
stimulation and sperm retrieval from the 
urine with oral sodium bicarbonate a 
few hours before collection of urine can 
be offered.12
Other Options
In men who have NOA and no sperm re-
trieved from surgery, or men with AZFa or 
AZFb deletion, use of donor sperm should 
be counselled. Couples should be fully 
counselled on the implications of the use 
of donor gametes. The couple also needs 
to understand the regulation of the law and 
the code of practice in different countries 
and regions, like the Human Fertilisation 
and Embryology Authority in the United 
Kingdom and the Council on Human Repro-
ductive Technology in Hong Kong. Adoption 
and childlessness are the other two options. 
CONCLUSION
Semen analysis is the most common 
method for assessment of fertility status 
of the male partner, although its prognos-
tic value is limited except in the case of 
azoospermia. The management of male 
infertility should be based on the aeti-
ology if it is known. For male infertility 
with unknown cause, empirical treatment 
methods such as IUI, IVF and ICSI can be 
offered. The development of these meth-
ods offers hope for couples suffering 
from male infertility, even for those with 
severe sperm problems or azoospermia. 
About the Authors
Dr Lee is Associate Consultant, Dr Ng is Clinical As-
sociate Professor, and Dr Ho is Professor and Chair 
of Obstetrics and Gynaecology, in the Department of 
Obstetrics and Gynaecology, Queen Mary Hospital, 
The University of Hong Kong, Hong Kong SAR.
A complete list of references can be obtained upon request to 
the editor.
CME Questions
This continuing medical education service is brought to you by the Medical Progress Institute, an institute 
dedicated to CME learning. Read the article ‘Male Infertility’ and answer the following questions. This 
JPOG article has been accredited for CME by the Hong Kong College of Obstetricians and Gynaecologists.
CME Answers for JPOG Jan/Feb 2012
HKCOG CME Article: Management of Pregnancies 
With Previous Caesarean Section
ANSWERS
 1 2 3 4 5 6 7 8 9 10
 T F F T T T T T T F
Name in BLOCK CAPITALS: 
Signature: 
Date: 
Please mail your completed answer sheet back to:
The Secretariat
Hong Kong College of Obstetricians & Gynaecologists
Room 805, Hong Kong Academy of Medicine Jockey Club Building
99 Wong Chuk Hang Road, Aberdeen, Hong Kong
CME Article
Male Infertility
Answer True or False to the questions below.
1. Male factor infertility accounts for 10% of subfertility problems.
2. Klinefelter syndrome is a major chromosomal abnormality found in patients with non-obstructive 
azoospermia.
3. Tests for CFTR gene mutation should not be offered to men with congenital bilateral absence of the 
vas deferens in various Caucasian populations.
4. Tests for  Y chromosome microdeletion in the AZF region have prognostic value in the success of 
surgical retrieval of sperm.
5. Bromocriptine can improve semen parameters and pregnancy outcomes in men with 
hyperprolactinaemia.
6. Tests for DNA fragmentation should not be used routinely in the investigation of infertility.
7. Non-obstructive azoospermia can be classified as due to gonadal failure or hypogonadotrophic 
hypogonadism.
8. Induction of spermatogenesis with pulsatile gonadotrophin-releasing hormone (GnRH) or 
gonadotrophins is the treatment of choice for men with hypogonadotrophic hypogonadism.
9. The use of GnRH antagonists in intrauterine insemination cycles can improve the pregnancy rate.
10. Antioxidant treatment can clearly improve the sperm parameters.
 True False
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